Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05239728
Title A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS


No variant requirements are available.